| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Friday’s Close |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | $386.665 | $41.78B | N/A |
Implied Volatility Surging for Regeneron (REGN) Stock Options
http://www.zacks.com/stock/news/432100/implied-volatility-surging-for-regeneron-regn-stock-options?cid=CS-ZC-FT-432100
Jun 20, 2019 - Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.
0
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
http://www.zacks.com/stock/news/431676/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data?cid=CS-ZC-FT-431676
Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
0
Alnylam Completes Enrollment in Phase III Study of Lumasiran
http://www.zacks.com/stock/news/431112/alnylam-completes-enrollment-in-phase-iii-study-of-lumasiran?cid=CS-ZC-FT-431112
Jun 18, 2019 - Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
0
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
http://www.zacks.com/stock/news/430443/regeneron-regn-presents-positive-data-on-lymphoma-candidate?cid=CS-ZC-FT-430443
Jun 17, 2019 - Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
0
Alnylam Completes Rolling NDA Submission to FDA for Givosiran
http://www.zacks.com/stock/news/425850/alnylam-completes-rolling-nda-submission-to-fda-for-givosiran?cid=CS-ZC-FT-425850
Jun 06, 2019 - Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
0
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
http://www.zacks.com/stock/news/424909/glaxos-nucala-gets-chmp-nod-for-2-self-administered-options?cid=CS-ZC-FT-424909
Jun 05, 2019 - GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
0
Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service
http://www.zacks.com/research-daily/418566/top-analyst-reports-for-home-depot-phillip-morris-united-parcel-service?cid=CS-ZC-FT-418566
May 23, 2019 - Top Analyst Reports for Home Depot, Phillip Morris & United Parcel Service
0
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
http://www.zacks.com/stock/news/417074/adverum-up-as-fda-lifts-hold-on-cohort-of-wet-amd-study?cid=CS-ZC-FT-417074
May 20, 2019 - Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
0
Pfizer's Eczema Candidate Meets All Goals in Phase III Study
http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939
May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
0
Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
http://www.zacks.com/stock/news/414511/biotech-stock-roundup-fda-nod-for-regns-eylea-in-dr-tie-ups-other-updates?cid=CS-ZC-FT-414511
May 15, 2019 - Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.
0
Page 1>